FY2024 EPS Estimate for LeMaitre Vascular Raised by Analyst

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Stock analysts at Barrington Research upped their FY2024 earnings per share (EPS) estimates for LeMaitre Vascular in a research note issued to investors on Friday, November 1st. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $1.94 for the year, up from their previous estimate of $1.87. Barrington Research currently has a “Outperform” rating and a $93.00 target price on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.55 EPS and FY2025 earnings at $2.28 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 15.6% on a year-over-year basis.

LMAT has been the subject of a number of other reports. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Finally, JMP Securities upped their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Trading Up 2.4 %

Shares of LMAT stock opened at $98.63 on Monday. The company has a market cap of $2.22 billion, a P/E ratio of 53.90, a PEG ratio of 2.38 and a beta of 0.89. The firm has a fifty day moving average price of $89.88 and a 200 day moving average price of $83.74. LeMaitre Vascular has a 12 month low of $47.72 and a 12 month high of $101.67.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.79% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently made changes to their positions in LMAT. NBC Securities Inc. grew its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the period. West Oak Capital LLC purchased a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $58,000. USA Financial Formulas acquired a new position in LeMaitre Vascular during the third quarter worth $60,000. Finally, nVerses Capital LLC boosted its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.